|
11 Companies |
|
6 Products |
|
6 Products |
|
17 Mechanisms of Action |
|
0 Trials |
|
66 News |
|
| 12» |
- | ACAM2000 (smallpox (vaccinia) live vaccine) / Emergent Biosolutions
Phase classification: Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000 (clinicaltrials.gov) - Jan 30, 2018
P=N/A, N=14108, Completed, Sponsor: Emergent BioSolutions
Phase classification: P4 --> P=N/A
- || Trial initiation date: Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel (clinicaltrials.gov) - Jan 30, 2018
P=N/A, N=5001, Completed, Sponsor: Emergent BioSolutions
Phase classification: P4 --> P=N/A Initiation date: Dec 2008 --> Sep 2009
- Enrollment change, Trial termination: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Oct 25, 2017
P2, N=27, Terminated, Sponsor: ViroXis Corporation
Initiation date: Dec 2008 --> Sep 2009 N=60 --> 27 | Recruiting --> Terminated; Sponsor chose to close
- | CNJ-016 (vaccinia immune globulin intravenous (human)) / Emergent Biosolutions
Trial completion: Evaluation and Treatment of Eye Complications of Vaccinia Vaccination (clinicaltrials.gov) - Jun 30, 2017
P2, N=400, Completed, Sponsor: National Eye Institute (NEI)
N=60 --> 27 | Recruiting --> Terminated; Sponsor chose to close Recruiting --> Completed
- || Trial primary completion date: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - May 17, 2017
P2, N=60, Recruiting, Sponsor: ViroXis Corporation
Recruiting --> Completed Trial primary completion date: Oct 2016 --> Aug 2017
- |||| Enrollment open, Trial initiation date: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Apr 25, 2016
P2, N=60, Recruiting, Sponsor: ViroXis Corporation
Trial primary completion date: Oct 2016 --> Aug 2017 Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2016
- |||| ACAM2000 (smallpox (vaccinia) live vaccine) / Emergent Biosolutions
Trial completion, Enrollment change: Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000 (clinicaltrials.gov) - Feb 21, 2016
P4, N=14108, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2016 Active, not recruiting --> Completed | N=20000 --> 14108
- | Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial completion: A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 20, 2016
P2, N=25, Completed, Sponsor: Jennerex Biotherapeutics
Active, not recruiting --> Completed | N=20000 --> 14108 Active, not recruiting --> Completed
- | Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial completion, Metastases: Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma (clinicaltrials.gov) - Jan 11, 2016
P1, N=15, Completed, Sponsor: Jennerex Biotherapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: Safety Study of Modified Vaccinia Virus to Cancer (clinicaltrials.gov) - Dec 29, 2015
P1, N=26, Completed, Sponsor: David Bartlett
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=36 --> 26
- Trial completion: Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=677, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed | N=36 --> 26 Recruiting --> Completed
- | Trial completion: Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum (clinicaltrials.gov) - Oct 1, 2015
P2/3, N=53, Completed, Sponsor: Jordi Gol i Gurina Foundation
Recruiting --> Completed Recruiting --> Completed
- | olvimulogene nanivacirepvec (GL-ONC1) / Genelux
Trial completion, Enrollment change, Combination therapy, Metastases: Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer (clinicaltrials.gov) - Aug 25, 2015
P1, N=19, Completed, Sponsor: Genelux Corporation
Recruiting --> Completed Active, not recruiting --> Completed | N=24 --> 19
- Enrollment change: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Jul 13, 2015
P2, N=60, Not yet recruiting, Sponsor: ViroXis Corporation
Active, not recruiting --> Completed | N=24 --> 19 N=200 --> 60
- Trial initiation date, Trial primary completion date: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Jul 8, 2015
P2, N=200, Not yet recruiting, Sponsor: ViroXis Corporation
N=200 --> 60 Initiation date: Jan 2015 --> Sep 2015 | Trial primary completion date: Aug 2015 --> Aug 2016
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Trial completion: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE (clinicaltrials.gov) - May 22, 2015
P2, N=435, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Jan 2015 --> Sep 2015 | Trial primary completion date: Aug 2015 --> Aug 2016 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) (clinicaltrials.gov) - May 6, 2015
P2a, N=150, Completed, Sponsor: National Center for AIDS/STD Control and Prevention, China CDC
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2014
- ||| ACAM2000 (smallpox (vaccinia) live vaccine) / Emergent Biosolutions
Enrollment closed: Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000 (clinicaltrials.gov) - Mar 18, 2015
P4, N=20000, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- |||| Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial completion, Trial initiation date, Trial primary completion date, Metastases: A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (clinicaltrials.gov) - Mar 11, 2015
P2, N=129, Completed, Sponsor: Jennerex Biotherapeutics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Initiation date: Aug 2011 --> Dec 2008 | Trial primary completion date: Oct 2013 --> Dec 2011
- olvimulogene nanivacirepvec (GL-ONC1) / Genelux
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer (clinicaltrials.gov) - Mar 10, 2015
P1, N=24, Active, not recruiting, Sponsor: Genelux Corporation
Active, not recruiting --> Completed | Initiation date: Aug 2011 --> Dec 2008 | Trial primary completion date: Oct 2013 --> Dec 2011 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jun 2015
- olvimulogene nanivacirepvec (GL-ONC1) / Genelux
Trial completion, Enrollment change, Oncolytic virus, Metastases: A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis (clinicaltrials.gov) - Mar 10, 2015
P1/2, N=9, Completed, Sponsor: Genelux GmbH
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jun 2015 Recruiting --> Completed | N=30 --> 9
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial completion: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (clinicaltrials.gov) - Jan 15, 2015
P1, N=6, Completed, Sponsor: Jennerex Biotherapeutics
Recruiting --> Completed | N=30 --> 9 Active, not recruiting --> Completed
- | Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial completion: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors (clinicaltrials.gov) - Jan 15, 2015
P1, N=23, Completed, Sponsor: Jennerex Biotherapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Enrollment closed, Trial primary completion date: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE (clinicaltrials.gov) - Dec 19, 2014
P2, N=435, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Mar 2015
- | NN1213 / Novo Nordisk
Trial completion: Combination Study With MVA BN and Dryvax (clinicaltrials.gov) - Dec 17, 2014
P1, N=91, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Mar 2015 Active, not recruiting --> Completed
- ||| Trial initiation date: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Dec 10, 2014
P2, N=200, Not yet recruiting, Sponsor: ViroXis Corporation
Active, not recruiting --> Completed Initiation date: Jul 2014 --> Jan 2015
- Trial completion date: Expanded Dryvax Dilution Study in Previously Vaccinated Adults (clinicaltrials.gov) - Dec 6, 2014
P2, N=927, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Jul 2014 --> Jan 2015 Trial completion date: Oct 2004 --> Dec 2003
- Enrollment open, Trial primary completion date: Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=750, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial completion date: Oct 2004 --> Dec 2003 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2014 --> Feb 2015
- | NN1213 / Novo Nordisk
Trial completion: Expanded Dryvax Dilution Study in Previously Vaccinated Adults (clinicaltrials.gov) - Dec 3, 2014
P2, N=927, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2014 --> Feb 2015 No longer recruiting --> Completed
- ||||||| JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Trial completion, Trial primary completion date: A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE (clinicaltrials.gov) - Sep 28, 2014
P3, N=4005, Completed, Sponsor: Bavarian Nordic
No longer recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Nov 2013
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Enrollment change: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE (clinicaltrials.gov) - Jul 27, 2014
P2, N=440, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Nov 2013 N=352 --> 440
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Trial primary completion date: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE (clinicaltrials.gov) - Apr 30, 2014
P2, N=352, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=352 --> 440 Trial primary completion date: Dec 2013 --> Sep 2014
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Enrollment open: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE (clinicaltrials.gov) - Apr 30, 2014
P2, N=352, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2013 --> Sep 2014 Suspended --> Recruiting
- ||| Trial completion: Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=5001, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Suspended --> Recruiting Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=15, Completed, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||| NN1213 / Novo Nordisk
Trial completion: Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults (clinicaltrials.gov) - Feb 22, 2014
P1, N=110, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
No longer recruiting --> Completed Not yet recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Human Immune Responses Smallpox (clinicaltrials.gov) - Feb 22, 2014
P1, N=45, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Dressing Preparations for Smallpox (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=102, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=80, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| ACAM2000 (smallpox (vaccinia) live vaccine) / Emergent Biosolutions
Trial completion: Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination (clinicaltrials.gov) - Feb 22, 2014
P2, N=353, Completed, Sponsor: Sanofi
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| ACAM2000 (smallpox (vaccinia) live vaccine) / Emergent Biosolutions
Trial completion: Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults (clinicaltrials.gov) - Feb 22, 2014
P2, N=357, Completed, Sponsor: Sanofi
No longer recruiting --> Completed No longer recruiting --> Completed
- ||| NN1213 / Novo Nordisk
Trial completion: Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax (clinicaltrials.gov) - Feb 22, 2014
P1, N=350, Completed, Sponsor: DynPort Vaccine Company LLC, A CSC Company
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Dryvax Dilution-Prev Vacc Adults (clinicaltrials.gov) - Feb 22, 2014
P2, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial withdrawal: Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) (clinicaltrials.gov) - Jan 16, 2014
P1, N=0, Withdrawn, Sponsor: Sanofi Pasteur, a Sanofi Company
No longer recruiting --> Completed Terminated --> Withdrawn
- ||||| New P2 trial: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Dec 29, 2013
P2, N=200, Not yet recruiting, Sponsor: ViroXis Corporation
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Trial suspension: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE (clinicaltrials.gov) - Nov 20, 2013
P2, N=352, Suspended, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Terminated --> Withdrawn Recruiting --> Suspended
- ||||| JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Enrollment closed: A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE (clinicaltrials.gov) - Nov 18, 2013
P3, N=4000, Active, not recruiting, Sponsor: Bavarian Nordic
Recruiting --> Suspended Recruiting --> Active, not recruiting
- Enrollment closed: Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) (clinicaltrials.gov) - Jul 13, 2013
P2a, N=150, Active, not recruiting, Sponsor: National Center for AIDS/STD Control and Prevention, China CDC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Trial completion: Safety and Efficacy of CJ-50300 in Healthy Volunteers (clinicaltrials.gov) - Jul 6, 2013
P2/3, N=123, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| Trial completion: Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers (clinicaltrials.gov) - May 29, 2013
P3, N=145, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Completed Active, not recruiting --> Completed